Drug profile · INN
dalteparin sodium
FRAGMIN
dalteparin sodium (FRAGMIN) is a antithrombin-iii activator. Route of administration: injection. Current US regulatory status: approved.
Drug details — dalteparin sodium
- US status
- approved
- Class
- —
- Route
- INJECTION
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
dalteparin sodium (FRAGMIN) is a antithrombin-iii activator. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
Antithrombin-III activator
Primary target: Antithrombin-III
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is dalteparin sodium?
dalteparin sodium (FRAGMIN) is a antithrombin-iii activator. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for dalteparin sodium?
FRAGMIN is a marketed brand name for dalteparin sodium. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of dalteparin sodium?
dalteparin sodium has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.